Sex differences in inflammation and inflammatory pain in cyclooxygenase-deficient mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 291, Issue 2, 2006, Pages

  Chillingworth, Naomi L ^a,d   Morham, Scott G ^b   Donaldson, Lucy F ^a,c  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b Myriad Genetic Laboratories   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d University of Bath   (United Kingdom)

Author keywords

Allodynia; Arthritis; Hyperalgesia

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ALLODYNIA; ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; EDEMA; ENZYME DEFICIENCY; EXPERIMENTAL MODEL; GENE; GENE DISRUPTION; GENE EXPRESSION; GENOTYPE; HYPERALGESIA; INFLAMMATION; JOINT DESTRUCTION; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; SEX DIFFERENCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EDEMA; FEMALE; HYPERALGESIA; INFLAMMATION; JOINTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PAIN; PAIN MEASUREMENT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SEX CHARACTERISTICS;

EID: 33745862316     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00901.2005     Document Type: Article

References (83)

1. Ackerman NR, Kappas K, and Maloney P. Possible disease-modifying effects of naproxen in the adjuvant-arthritic rat. Agents Actions 15: 428-435, 1984.
2. Ackerman NR, Rooks WH, 2nd Shott L, Genant H, Maloney P, and West E. Effects of naproxen on connective tissue changes in the adjuvant arthritic rat. Arthritis Rheum 22: 1365-1374, 1979.
3. Affleck G, Tennen H, Keefe FJ, Lefebvre JC, Kashikar-Zuck S, Wright K, Starr K, and Caldwell DS. Everyday life with osteoarthritis or rheumatoid arthritis: independent effects of disease and gender on daily pain, mood, and coping. Pain 83: 601-609, 1999.
4. Ainsworth L, Budelier K, Clinesmith M, Fiedler A, Landstrom R, Leeper BJ, Moeller L, Mutch S, O'Dell K, and Ross J. Transcutaneous electrical nerve stimulation (TENS) reduces chronic hyperalgesia induced by muscle inflammation. Pain 120: 182-187, 2006.
5. Aloisi AM, Ceccarelli I, and Fiorenzani P. Gonadectomy affects hormonal and behavioral responses to repetitive nociceptive stimulation in male rats. Ann NY Acad Sci 1007: 232-237, 2003.
6. Aloisi AM, Porro CA, Cavazzuti M, Baraldi P, and Carli G. 'Mirror pain' in the formalin test: behavioral and 2-deoxyglucose studies. Pain 55: 267-273, 1993.
7. Arthritis Research Campaign. Arthritis: The Big Picture, 2002. [The data are available at http://www.arc.org.uk/about_arth/bigpic.htm]
8. Ballou LR, Botting RM, Goorha S, Zhang J, and Vane JR. Nociception in cyclooxygenase isozyme-deficient mice. Proc Natl Acad Sci USA 97: 10272-10276, 2000.
9. Beiche F, Scheuerer S, Brune K, Geisslinger G, and Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390: 165-169, 1996.
10. Berkley KJ. Sex differences in pain. Behav Brain Sci 20: 371-380; discussion 435-513, 1997.
11. Bertolini A, Ottani A, and Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res 44: 437-450, 2001.
12. Blackham A, Burns JW, Farmer JB, Radziwonik H, and Westwick J. An X-ray analysis of adjuvant arthritis in the rat. The effect of prednisolone and indomethacin. Agents Actions 7: 145-151, 1977.
13. Bradshaw H, Miller J, Ling Q, Malsnee K, and Ruda MA. Sex differences and phases of the estrous cycle alter the response of spinal cord dynorphin neurons to peripheral inflammation and hyperalgesia. Pain 85: 93-99, 2000.
14. Breder CD, Dewitt D, and Kraig RP. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 355: 296-315, 1995.
15. Breder CD, Smith WL, Raz A, Masferrer J, Seibert K, Needleman P, and Saper CB. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 322: 409-438, 1992.
16. Butler SH, Godefroy F, Besson JM, and Weil-Fugazza J.. A limited arthritic model for chronic pain studies in the rat. Pain 48: 73-81, 1992.
17. Chen J, Luo C, Li H, and Chen H. Primary hyperalgesia to mechanical and heat stimuli following subcutaneous bee venom injection into the plantar surface of hindpaw in the conscious rat: a comparative study with the formalin test. Pain 83: 67-76, 1999.
18. Chillingworth NL and Donaldson LF. Characterisation of a Freund's complete adjuvant-induced model of chronic arthritis in mice. J Neurosci Methods 128: 45-52, 2003.
19. Chopra B, Giblett S, Little JG, Donaldson LF, Tate S, Evans RJ, and Grubb BD. Cyclooxygenase-1 is a marker for a subpopulation of putative nociceptive neurons in rat dorsal root ganglia. Eur J Neurosci 12: 911-920, 2000.
20. Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, Riendeau D, and Mancini JA. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model. J Immunol 170: 4738-4744, 2003.
21. Crofford LJ. Is there a place for non-selective NSAIDs in the treatment of arthritis? Joint Bone Spine 69: 4-7, 2002.
22. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, Epps HR, and Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 93: 1095-1101, 1994.
23. Dina OA, Aley KO, Isenberg W, Messing RO, and Levine JD. Sex hormones regulate the contribution of PKCepsilon and PKA signalling in inflammatory pain in the rat. Eur J Neurosci 13: 2227-2233, 2001.
24. Dirig DM, Isakson PC, and Yaksh TL. Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats. J Pharmacol Exp Ther 285: 1031-1038., 1998.
25. Dirig DM, Konin GP, Isakson PC, and Yaksh TL. Effect of spinal cyclooxygenase inhibitors in rat using the formalin test and in vitro prostaglandin E2 release. Eur J Pharmacol 331: 155-160, 1997.
26. Dirig DM and Yaksh TL. Spinal synthesis and release of prostanoids after peripheral injury and inflammation. Adv Exp Med Biol 469: 401-408, 1999.
27. Dominick KL, Ahern FM, Gold CH, and Heller DA. Gender differences in NSAID use among older adults with osteoarthritis. Ann Pharmacother 37: 1566-1571, 2003.
28. Donaldson LF. The primary Afferent Nociceptor and Neuropeptide Gene Expression: Importance in Experimental Arthritis. (PhD thesis). Edinburgh, UK: University of Edinburgh, 1994.
29. Donaldson LF. Unilateral arthritis: contralateral effects. Trends Neurosci 22: 495-496, 1999.
30. Donaldson LF, Seckl JR, and McQueen DS. A discrete adjuvant-induced monoarthritis in the rat: effects of adjuvant dose. J Neurosci Methods 49: 5-10, 1993.
31. Dou W, Jiao Y, Goorha S, Raghow R, and Ballou LR. Nociception and the differential expression of cyclooxygenase-1 (COX-1), the COX-1 variant retaining intron-1 (COX-1v), and COX-2 in mouse dorsal root ganglia (DRG). Prostaglandins Other Lipid Mediat 74: 29-43, 2004.
32. Egan CG, Lockhart JC, Ferrell WR, Day SM, and McLean JS. Pathophysiological basis of acute inflammatory hyperaemia in the rat knee: roles of cyclo-oxygenase-1 and -2. J Physiol 539: 579-587, 2002.
33. Egan KM, Lawson JA, Fries S, Koller B, Rader DJ, Smyth EM, and FitzGerald GA. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306: 1954-1957, 2004.
34. Euchenhofer C, Maihofner C, Brune K, Tegeder I, and Geisslinger G. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett 248: 25-28, 1998.
35. Francischi JN, Chaves CT, Moura AC, Lima AS, Rocha OA, Ferreira-Alves DL, and Bakhle YS. Selective inhibitors of cyclooxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation. Br J Pharmacol 137: 837-844, 2002.
36. Friedman ES, LaNatra N, and Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg 6: 449-459, 2002.
37. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, and Levine JD. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 83: 339-345, 1999.
38. Gentilli M, Mazoit JX, Bouaziz H, Fletcher D, Casper RF, Benhamou D, and Savouret JF. Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci 68: 1317-1321, 2001.
39. Gilroy DW, Tomlinson A, Greenslade K, Seed MP, and Willoughby DA. The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of Mycobacterium tuberculosis-induced monoarticular arthritis in the rat. Inflammation 22: 509-519, 1998.
40. Gilroy DW, Tomlinson A, and Willoughby DA. Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. Inflamm Res 47: 79-85, 1998.
41. Gilroy DW, Tomlinson A, and Willoughby DA. Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. Eur J Pharmacol 355: 211-217, 1998.
42. Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ, Gavins FNE, Perretti M, Morris JF, Buckingham JC, and Flower RJ. Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J 17: 253-255, 2003.
43. Harder AT and An YH. The mechanisms of the inhibitory effects of nonsteroidal anti-inflammatory drugs on bone healing: A concise review. J Clin Pharmacol 43: 807-815, 2003.
44. Hargreaves K, Dubner R, Brown F, Flores C, and Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88, 1988.
45. Harley C and Wagner S. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: Data from managed care. Clin Ther 25: 139-149, 2003.
46. Hay CH, Trevethick MA, Wheeldon A, Bowers JS, and de Belleroche JS. The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia. Neuroscience 78: 843-850, 1997.
47. Helin-Salmivaara A, Klaukka T, and Huupponen R. Heavy users of non-steroidal anti-inflammatory drugs: a nationwide prescription database study in Finland. Eur J Clin Pharmacol 59: 477-482, 2003.
48. Holmdahl R. Female preponderance for development of arthritis in rats is influenced by both sex chromosomes and sex steroids. Scand J Immunol 42: 104-109, 1995.
49. Igarashi K, Woo JT, and Stern PH. Effects of a selective cyclooxygenase-2 inhibitor, celeCOXib, on bone resorption and osteoclastogenesis in vitro. Biochem Pharmacol 63: 523-532, 2002.
50. Iniguez MA, Pablos JL, Carreira PE, Cabre F, and Gomez-Reino JJ. Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br J Rheumatol 37: 773-778, 1998.
51. Joseph EK and Levine JD. Sexual dimorphism for protein kinase c epsilon signaling in a rat model of vincristine-induced painful peripheral neuropathy. Neuroscience 119: 831-838, 2003.
52. Sluka KA, Kalra A, and Moore SA. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve 24: 37-46, 2001.
53. Kang RY, Freire-Moar J, Sigal E, and Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 35: 711-718, 1996.
54. Koltzenburg M, Wall PD, and McMahon SB. Does the right side know what the left is doing? Trends Neurosci 22: 122-127, 1999.
55. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim, HS, and Smithies O. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 83: 483-492, 1995.
56. Lee YH, Choi SJ, Kim A, Kim CH, Ji JD, and Song GG. Expression of cyclooxygenase-1 and -2 in rheumatoid arthritis synovium. J Korean Med Sci 15: 88-92, 2000.
57. Martinez RV, Reval M, Campos MD, Terron JA, Dominguez R, and Lopez-Munoz FJ. Involvement of peripheral cyclooxygenase-1 and cyclooxygenase-2 in inflammatory pain. J Pharm Pharmacol 54: 405-412, 2002.
58. Mazario J, Gaitan G, and Herrero JF. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neuropharmacology 40: 937-946, 2001.
59. Meli R, Antonelli E, and Cirino G. Analgesia and cyclo-oxygenase inhibitors. Dig Liver Dis 33: S8-S11, 2001.
60. Miyagi M, Morishita M, and Iwamoto Y. Effects of sex hormones on production of prostaglandin E2 by human peripheral monocytes. J Periodontol 64: 1075-1078, 1993.
61. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, and Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482, 1995.
62. Myers LK, Kang AH, Postlethwaite AE, Rosloniec EF, Morham SG, Shlopov BV, Goorha S, and Ballou LR. The genetic ablation of cyclooxygenase 2 prevents the development of autoimmune arthritis. Arthritis Rheum 43: 2687-2693. 2000.
63. Neeraja S, Sreenath AS, Reddy PR, and Reddanna P. Expression of cyclooxygenase-2 in rat testis. Reprod Biomed Online 6: 302-309, 2003.
64. Ochi T and Goto T. Anti-inflammatory activity of a novel selective cyclooxygenase-2 inhibitor, FR140423, on type II collagen-induced arthritis in Lewis rats. Prostaglandins Other Lipid Mediat 66: 317-327, 2001.
65. Ospina JA, Krause DN, and Duckles SP. 17β-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 33: 600-605, 2002.
66. Pinheiro RM and Calixto JB. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflamm Res 51: 603-610, 2002.
67. Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, Pahl A, Brune K, Narumiya S, Muller U, and Zeilhofer HU. Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 115: 673-679, 2005.
68. Roos KL and Simmons DL. Cyclooxygenase variants: the role of alternative splicing. Biochem Biophys Res Commun 338: 62-69, 2005.
69. Samad TA, Moore KA, Sapirstein A, Billet S, Allchorne A, Poole S, Bonventre JV, and Woolf CJ. Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 410: 471-475, 2001.
70. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, and Bjarnason I. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 122: 1913-1923, 2002.
71. Siqueira-Junior JM, Peters RR, Brum-Fernandes AJ, and Ribeiro-do-Valle RM. Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice. Pharmacol Res 48: 437-443, 2003.
72. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, and Isakson PC. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95: 13313-13318, 1998.
73. Suzuki M, Hayash I, Nara Y, Kumaga Y, Okamoto H, Hoka S, and Majima M. Participation of cyclooxygenases in cutaneous thermal nociception under non-inflamed and inflamed conditions. Inflamm Res 50: 283-287, 2001.
74. Turnbach ME, Seth Spraggins D, and Randich A. Spinal administration of prostaglandin E2 or prostaglandin F2α primarily produces mechanical hyperalgesia that is mediated by nociceptive specific spinal dorsal horn neurons. Pain 97: 33-45, 2002.
75. Vanegas H and Schaible HG. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol 64: 327-363, 2001.
76. Walker JS and Carmody JJ. Experimental pain in healthy human subjects: gender differences in nociception and in response to ibuprofen. Anesth Analg 86: 1257-1262, 1998.
77. Wallace JL, Bak A, McKnight W, Asfaha S, Sharkey KA, and MacNaughton WK. Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gastroenterology 115: 101-109, 1998.
78. Wallace JL, McKnight W, Reuter BK, and Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 119: 706-714, 2000.
79. Wilder RL. Rheumatoid arthritis: epidemiology, patholgy, and pathogenesis In: Primer on the Rhuematic Diseases (10th ed.), edited by Schumacher R, Klippel J, and Koopman W. Atlanta, GA: The Arthritis Foundation, 1993, p. 86-89.
80. Wilder RL, Calandra GB, Garvin AJ, Wright KD, and Hansen CT. Strain and sex variation in the susceptibility to streptococcal cell wall-induced polyarthritis in the rat. Arthritis Rheum 25: 1064-1072, 1982.
81. Willingale HL, Gardiner NJ, McLymont N, Giblett S, and Grubb BD. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol 122: 1593-1604, 1997.
82. Yamada R, Sano H, Hla T, Hashiramoto A, Kawahito Y, Mukai S, Kohno M, Tsubouchi Y, Inoue M, Komatsu A, Inoue K, and Kondo M. Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis. Biochem Biophys Res Commun 269: 415-421, 2000.
83. Zhao Z, Chen SR, Eisenach JC, Busija DW, and Pan HL. Spinal cyclooxygenase-2 is involved in development of allodynia after nerve injury in rats. Neuroscience 97: 743-748, 2000.